Chester County News and Community Website
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The …
Read More
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) this weekannounced results from the Phase 3 ROMAN trial of avasopasem manganese (avasopasem) for severe oral mucositis (SOM) in patients with locally …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration announced it recently awarded 11 new clinical trial research grants, equaling more than $25 million of funding over the next four …
Read More
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced data from 30 patients enrolled in the proof-of-concept study of TRV027, the Company’s novel AT1 receptor selective agonist, in hospitalized COVID-19 patients. The …
Read More
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar® Advanced Therapy for Mental Health than with TMS treatments that claim deeper …
Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar® Advanced Therapy for Mental Health than with TMS treatments that claim deeper …
Read More
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center, efficacy and safety (RECONNECT) Phase 3 trial.
Read More
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) announced details of the clinical research presented last week at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting in Las …
Read More MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX) announced final results from its Phase 1/2 pilot trial of its dismutase mimetic, GC4419, versus placebo, in patients with unresectable or borderline …
Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the publication this week of results from the Company’s open-label Phase 2 BELIEVE (Open Label Study to Assess the Safety and Efficacy …
Read More